Related Experiment Video
Updated: Mar 8, 2026

A Semi-Automated and Reproducible Biological-Based Method to Quantify Calcium Deposition In Vitro
Published on: June 2, 2022
Relation of fibroblast growth factor-23 and cardiovascular calcification in end-stage kidney disease patients on
Tarek Zakaria El Baz1, Osama Ahmed Khamis1, Osama Ashry Ahmed Gheith2
1Department of Internal Medicine and Nephrology, Faculty of Medicine, Al Azhar University, Cairo, Egypt.
Insights
Elevated fibroblast growth factor 23 (FGF-23) is linked to vascular calcification in end-stage kidney disease (ESKD) patients undergoing hemodialysis (HD). This FGF-23 elevation correlates with aortic and coronary artery calcification, highlighting a significant risk factor.
Area of Science:
- Nephrology
- Cardiology
- Biochemistry
Background:
- Cardiovascular disease causes over half of deaths in end-stage kidney disease (ESKD) patients.
- Elevated fibroblast growth factor 23 (FGF-23) is associated with mortality and peripheral calcification in hemodialysis (HD) patients.
- Vascular calcification, including aortic and peripheral, is linked to mortality in chronic kidney disease (CKD).
Purpose of the Study:
- To investigate the relationship between intact FGF-23 and cardiovascular calcification in ESKD patients on regular HD.
- To assess the prevalence of vascular calcification in this patient group.
- To explore correlations between FGF-23, calcification, and other risk factors.
Main Methods:
- Cross-sectional study of 60 clinically stable ESKD patients on regular HD.
- Evaluation of abdominal aortic calcification via X-ray, with CT scans for coronary artery calcification in affected patients.
- Assessment of lipid profile, dialysis adequacy, and plasma intact FGF-23 levels.
Main Results:
- Fifty percent of patients exhibited vascular calcification.
- Elevated plasma intact FGF-23 was observed in all patients, correlating positively with age, aortic calcification, coronary calcification, lipid profile, left ventricular mass index (LVMI), and inflammatory markers.
- Significant positive correlations were found between age and FGF-23, and between age, BMI, HD duration, and abdominal aortic calcification score.
Conclusions:
- Plasma intact FGF-23 is elevated in non-diabetic ESKD patients on HD and correlates significantly with vascular calcification.
- Vascular calcification is prevalent in this ESKD population, associated with traditional and non-traditional risk factors.
- FGF-23 may indirectly contribute to vascular calcification through its effects on mineral metabolism and parathyroid hormone.
Abstract:
More than half of deaths in end-stage kidney disease (ESKD) patients are due to cardiovascular disease. Elevated fibroblast growth factor 23 (FGF-23) was found to be associated with mortality in hemodialysis (HD) patients and correlates with peripheral calcification. Aortic calcification is associated with coronary artery calcification. Both aortic and peripheral vascular calcifications were associated with mortality in chronic kidney disease. We aimed to investigate the relation between intact FGF-23 and cardiovascular calcification in patients with ESKD who were maintained on regular HD. Sixty clinically stable ESKD patients on regular HD were enrolled into this cross-sectional study. They were evaluated by basal abdominal X-ray. They were divided into two groups: (Group A, n = 30), patients with abdominal aortic calcification who underwent multislice computerized tomography scan to measure coronary artery calcification score; and (Group B, n = 30), patients without abdominal aortic calcification. All of them were evaluated by lipid profile and dialysis adequacy parameters. Fifty percent of patients had vascular calcification. We found a significant positive correlation between age and intact FGF-23; significant positive correlations between age, body mass index, duration of HD, and abdominal aortic calcification score. FGF-23 of all patients was elevated and had significant positive correlation with aortic and coronary calcifications in addition to lipid profile, left ventricular mass index (LVMI), and inflammatory markers. Plasma intact FGF-23 was elevated in nondiabetic ESKD patients, and vascular calcification was prevalent in such group of patients with many traditional and nontraditional risk factors. Possibly through its disturbing effects on minerals and parathyroid hormone, FGF-23 might indirectly affect vascular calcification. LVMI was higher in patients with vascular calcification and correlated positively with it.
Related Concept Videos
Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration
Roles of Electrolytes: Calcium and Phosphate
The calcium concentration in blood plasma is primarily...
Chronic Kidney Disease III: Interprofessional Care
Chronic Kidney Disease II: Clinical Manifestations

